Shukra Pharmaceuticals (BOM:524632) ROCE % : 77.59% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Shukra Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shukra Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was 77.59%.

Shukra Pharmaceuticals ROCE % Historical Data

The historical data trend for Shukra Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shukra Pharmaceuticals ROCE % Chart

Shukra Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

3.00

0.24

0.40

5.06

17.02

Shukra Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															1.79	49.43	6.30	38.56	77.59

Shukra Pharmaceuticals ROCE % Calculation

Shukra Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	46.973	/	( ( (351.127 - 123.765)	+	(749.664 - 425.062) )	/ 2 )
	=	46.973	/	( (227.362	+	324.602)	/ 2 )
	=	46.973	/	275.982
	=	17.02 %

Shukra Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	383.804	/	( ( (743.492 - 248.867)	+	(0 - 0) )	/ 1 )
	=	383.804	/	( ( 494.625	+	0 )	/ 1 )
	=	383.804	/	494.625
	=	77.59 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Shukra Pharmaceuticals (BOM:524632) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shukra Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Shukra Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shukra Pharmaceuticals (BOM:524632) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shukra Pharmaceuticals Ltd (BOM:524632) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Judges Bunglow Road, Bodakdev, 3rd Floor, Veer House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054

Website

https://www.shukrapharmaceuticals.com

Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments; pharmaceutical and Laboratory. Its product portfolio includes antibiotics, antibiotics, quinolones, macrolides, anti-bacterial, anti-fungal, anti-malarial, anti-viral, antiprotozoal, anti-anthelmintic, anti-depressant, anti-manic, anti-emetic, beta-blockers, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.

Shukra Pharmaceuticals (BOM:524632) Headlines

No Headlines